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Abstract
Objective: To evaluate the incidence, predictors and outcomes of female patients
with patient-prosthesis mismatch (PPM) following transcatheter aortic valve interven-
tion (TAVI) for severe aortic stenosis (AS).
Background: Female AS TAVI recipients have a significantly lower mortality than sur-
gical aortic valve replacement (SAVR) recipients, which could be attributed to the
potentially lower PPM rates. TAVI has been associated with lower rates of PPM com-
pared to SAVR. PPM in females post TAVI has not been investigated to date.
Methods: The WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implan-
tation) registry is a multicenter registry of women undergoing TAVR for severe symp-
tomatic AS. Two hundred and fifty patients with detailed periprocedural and follow-
up echocardiographic investigations were included in the WIN-TAVI echocardio-
graphic sub-study. PPM was defined as per European guidelines stratified by the
presence of obesity.
Results: The incidence of PPM in our population was 32.8%. Patients with PPM had
significantly higher BMI (27.4 ± 6.1 vs. 25.2 ± 5.0, p = .002), smaller sized valves
implanted (percentage of TAVI ≤23 mm 61% vs. 29.2%, PPM vs. no PPM, p < .001)
and were more often treated with balloon expandable valves (48.3 vs. 32.5%,
p < .001) rather than self expanding ones (26.3 vs. 52.8%, <.001). BMI (OR = 1.08;
95%CI 1.02–1.14, p = .011) and valve size ≤23 mm (OR = 3.00 95%CI 1.14–7.94,
p = .027) were the only independent predictors of PPM. There was no significant
interaction between valve size and valve type (p = .203). No significant differences
were observed in 1-year mortality or major adverse cardiovascular events.
Conclusions: PPM in females undergoing TAVI occurs in one third of patients. BMI
and valve size ≤23 mm are independent predictors. Larger registries are required to
determine the impact of PPM on future clinical outcomes.
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1 | INTRODUCTION
The concept of patient prosthesis mismatch (PPM) was first described
by Rahimtoola in 1978: “Mismatch can be considered to be present
when the effective prosthetic valve area, after insertion into the patient,
is less than that of a normal human valve.”1 This concept was revisited
by Pibarot et al2 who suggested the process of selecting the appropriate
sized prosthesis using the indexed effective orifice area (iEOA), derived
from the EOA of the prosthesis and the body surface area of the
patient. Pibarot et al proposed avoiding an iEOA less than 0.85 cm2/m2
to prevent PPM. This is based on the steep increase in the mean pres-
sure gradient whenever iEOA falls below this cut off. PPM is considered
to be haemodynamically insignificant if the iEOA is >0.85 cm2/m2, mod-
erate if between 0.65 and 0.85 cm2/m2, and severe if <0.65 cm2/m2.
However, for obese patients (body mass index [BMI] ≥30 kg/m2) lower
criteria may be more appropriate, given the hyperdynamic cardiac out-
put state.3 Indeed new definitions of PPM were introduced in the 2016
European Guidelines for obese patients with BMI over 30.4,5
In a recent meta-analysis6 PPM was seen in 35% of patients
undergoing transcatheter aortic valve implantation (TAVI), a figure
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TABLE 1 Baseline demographics, comorbidities, echocardiographic, and CT parameters in the two groups
Variable PPM = 1, N = 82 (32.8%) PPM = 0, N = 168 (67.2%) p-value
General demographics
Age, years 82.3 ± 7.3 83.1 ± 6.2 .374
BMI, kg/m2 27.4 ± 6.1 25.2 ± 5.0 .002
Height, cm 161 ± 5.4 157 ± 9.7 <.001
Weight, kg 71.4 ± 17.0 63.6 ± 15.2 <.001
Caucasian 76 (95.0%) 155 (97.5%) .447
Past medical history
Hypertension 62 (76.5%) 126 (75.4%) .850
Diabetes 24 (29.3%) 38 (22.6%) .253
Current smoker 2 (2.4%) 9 (5.4%) .512
Previous MI 5 (6.1%) 19 (11.3%) .189
Previous PCI 15 (18.3%) 46 (27.4%) .116
Previous CABG 10 (12.3%) 15 (8.9%) .401
Previous cardiac surgery 14 (17.1%) 26 (15.6%) .761
Previous stroke 9 (11.1%) 19 (11.3%) .963
Peripheral arterial disease 11 (13.4%) 14 (8.4%) .220
COPD 17 (20.7%) 47 (28.0%) .218
Home O2 2 (2.5%) 5 (3.0%) 1.000
CKD 24 (29.3%) 60 (36.1%) .282
Euroscore I 18.9 ± 12.8 19.2 ± 12.2 .854
STS score 8.7 ± 8.2 9.6 ± 9.4 .477
Porcelain aorta 4 (4.9%) 18 (10.7%) .132
High surgical risk 71 (86.6%) 143 (85.1%) .757
Pulmonary hypertension 21 (25.6%) 47 (28.1%) .673
Prior pacemaker 6 (7.3%) 13 (7.7%) .906
Anemia 26 (31.7%) 47 (28.3%) .581
Baseline echocardiography
LVEF<30% 3 (3.8%) 4 (2.4%) .685
LVEF 54.6 ± 11.3 56.4 ± 10.5 .220
Echo annulus size 21.9 ± 2.2 21.7 ± 2.0 .557
Peak gradient 78.5 ± 18.3 77.1 ± 24.3 .682
Mean gradient 47.9 ± 11.5 48.6 ± 15.6 .730
AVA 0.7 ± 0.4 0.6 ± 0.2 .448
Baseline AR .152
None 24 (31.2%) 50 (32.3%)
Mild 35 (45.5%) 80 (51.6%)
Moderate 14 (18.2%) 24 (15.5%)
Severe 4 (5.2%) 1 (0.6%)
Baseline MR .266
None 12 (15.8%) 29 (18.1%)
Mild 44 (57.9%) 72 (45.0%)
Moderate 17 (22.4%) 53 (33.1%)
Severe 3 (3.9%) 6 (3.8%)
MSCT parameters (data available on 148 patients)
Aortic annulus perimeter (mm) 64.9 ± 21.5 71.6 ± 23.5 .159
Aortic annular calcification .801
(Continues)
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significantly lower to the one seen in patients undergoing surgical aor-
tic valve replacement (SAVR) (OR 0.23;95%CI 0.07–0.79). This finding
may be related to differences in TAVI valve design, such as the
absence of a sewing ring and the supra-annular location of the neo
valve in some of the TAVI valves. Although the annulus is not pre-
pared by excising calcium, as is done in surgery, transcatheter valves
are associated with a larger EOA and iEOA, and lower peak as well as
mean transprosthetic gradients.7-17
Large surgical registries and a recent meta-analysis have demon-
strated an association between PPM and decreased long-term sur-
vival.18-20 Female gender was found to be a predictor of PPM in a
recent literature review.21 A predisposition of female patients to PPM
was demonstrated. This effect of PPM on survival, however, was not
shown in a recent meta-analysis of TAVI trials.6 This finding, however,
needs to be interpreted cautiously given the much shorter follow up
times. Of interest, recent reports22 point toward an association
between severe PPM with subclinical valve thrombosis.
In a meta-analysis of patients with aortic stenosis (AS),23 among
females, TAVI recipients had a significantly lower mortality than SAVR
recipients, at 1 year (OR 0.68; 95%CI 0.50–0.94) and at 2 years
(OR 0.74; 95%CI 0.58–0.95). One of the suggested mechanisms for
the increased survival amongst females treated with TAVI was the
lower PPM rates which could facilitate greater recovery in left ventric-
ular systolic function.9,16,24
In the current study we aim to investigate the prevalence of PPM,
its predictors and associated outcomes in females undergoing TAVI
included in the WIN-TAVI (Women's INternational Transcatheter Aor-
tic Valve Implantation) registry.
2 | METHODS
The WIN-TAVI registry (NCT01819181) is an international, multicenter,
prospective, observational registry of women undergoing TAVR at
TABLE 1 (Continued)
Variable PPM = 1, N = 82 (32.8%) PPM = 0, N = 168 (67.2%) p-value
None 5 (8.1%) 8 (6.2%)
Mild 4 (6.5%) 12 (9.2%)
Moderate 29 (46.8%) 66 (50.8%)
Severe 24 (38.7%) 44 (33.8%)
Aortic root calcium score 711 ± 540 720 ± 532 .933
Minimal iliofemoral dimesion (mm) 7.3 ± 2.3 8.5 ± 2.9 .012
Coronary angiography
Number of coronary vessels diseased .354
0 35 (64.8%) 78 (62.4%)
1 14 (25.9%) 23 (18.4%)
2 2 (3.7%) 12 (9.6%)
3 3 (5.6%) 12 (9.6%)
LMS disease 5 (10.6%) 9 (8.7%) .765
Abbreviations: AR, aortic regurgitation; AVA, aortic valve area; BMI, body mass index; CABG, coronary artery bypass surgery; CKD, chronic kindey disease;
COPD, chronic obstructive pulmonary artery disease; iEOA, indexed estimated orifice area; LMS, left main stem; LVEF, left ventricular ejection fraction;
MI, myocardial infarction; MR, mitral regurgitation; MSCT, mutlislice computed tomography; PCI, percutaneous coronary intervention; PPM, patient-
prosthesis mismatch.
TABLE 2 Female specific
characteristics
Variable PPM = 1, N = 82 (32.8%) PPM = 0, N = 168 (67.2%) p-value
Hx of pregnancy 63 (76.8%) 111 (66.1%) .083
Gestational diabetes 1 (1.7%) 0 (0.0%) .365
Gestational hypertension 2 (3.4%) 2 (2.0%) .623
Age at menopause 49.2 ± 5.6 50.0 ± 4.4 .289
History of HRT use 5 (7.1%) 4 (2.7%) .150
Hx of gynecolofical Ca 1 (1.3%) 6 (3.7%) .432
Hx of gynecologic surgery 9 (11.3%) 28 (17.0%) .241
Hx of breast Ca 6 (8.1%) 14 (8.9%) .838
Hx of osteoporosis 17 (23.3%) 23 (15.2%) .140
Abbreviations: Ca, cancer; HRT, hormonal replacement therapy; Hx, history; iEOA, indexed estimated ori-
fice area; PPM, patient prosthesis mismatch.
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19 European and North American centers treated with commercially
available and approved TAVR devices and delivery systems for the
treatment of severe symptomatic AS. Details of the registry and eligibil-
ity criteria have been described in previous publications.25 Out of the
total of 1,019 patients, 250 patients who had detailed periprocedural
and follow-up echocardiographic investigations were included in the
WIN TAVI echocardiographic sub-study. PPM was defined4,5 as
• moderate if iEOA 0.85–0.66 and severe if iEOA ≤0.65 in patients
with BMI <30 kg/m2
• moderate if iEOA 0.70–0.56 and severe if iEOA ≤0.55 in patients
with BMI ≥30 kg/m2
All patients underwent multislice computed tomography (MSCT)
in their participating centre. Reporting of echocardiographic and
MSCT parameters was performed at each participating centre.
2.1 | Endpoints
The primary endpoint was Valve Academic Research Consortium
(VARC)-2 early safety (at 30 days); this is a composite of all-cause
mortality, stroke, life-threatening bleeding, acute kidney injury
(Stages 2 and 3), coronary artery obstruction, major vascular compli-
cation, and valve-related dysfunction requiring repeat procedure
TABLE 3 Procedural parameters in
patients with and without patient
prosthesis mismatch
Variable PPM = 1, N = 82 (32.8%) PPM = 0, N = 168 (67.2%) p-value
Type of valve inserted <.001
Edwards S3 22 (27.5%) 26 (16.0%)
Edwards XT 17 (21.3%) 28 (17.2%)
Evolut R 6 (7.5%) 16 (9.8%)
Corevalve 15 (18.8%) 70 (42.9%)
Direct flow 10 (12.5%) 5 (3.1%)
Portico 0 (0.0%) 2 (1.2%)
Lotus 9 (11.3%) 16 (9.8%)
ACURATE neo 1 (1.3%) 0 (0.0%)
Valve type <.001
Balloon expandable 39 (48.8%) 54 (33.1%)
Self-expanding 21 (26.3%) 86 (52.8%)
Others 20 (25.0%) 23 (14.1%)
Valve size <.001
20 mm 1 (1.2%) 0 (0.0%)
23 mm 49 (59.8%) 49 (29.2%)
25 mm 7 (8.5%) 13 (7.7%)
26 mm 19 (23.2%) 67 (39.9%)
27 mm 2 (2.4%) 2 (1.2%)
29 mm 4 (4.9%) 36 (21.4%)
31 mm 0 (0.0%) 1 (0.6%)
Valve ≤23 mm 50 (61.0%) 49 (29.2%) <.001
Paravalvular AR post TAVI .898
None 29 (55.8%) 37 (51.4%)
Mild 21 (40.4%) 32 (44.4%)
Moderate 2 (3.8%) 3 (4.2%)
Paravalvular AR at 6/12 1.000
None 13 (46.4%) 24 (49.0%)
Mild 14 (50.0%) 23 (46.9%)
Moderate 1 (3.6%) 2 (4.1%)
New pacemaker 11 (13.4%) 18 (10.7%) .531
Major vascular complications 9 (11.0%) 15 (8.9%) .606
Life threatening bleeding 2 (2.4%) 12 (7.1%) .154
Abbreviations: AR, aortic regurgitation; iEOA, indexed estimated orifice area; PPM, patient prosthesis
mismatch.
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(BAV, TAVI, or SAVR).26 Secondary endpoints included 1-year all
cause mortality, cardiovascular mortality, stroke and the composites
death or stroke, and major adverse cardiovascular events (death, MI,
or stroke).
2.1.1 | Statistical analysis
All continuous variables were tested for normality using the
Kolmogorov–Smirnov test. Categorical data are presented as frequen-
cies and percentages and were compared using the chi-square or
Fisher exact test. Continuous variables are presented as mean ± SD or
medians and interquartile range and were compared using Student's
t test or Wilcoxon signed rank test. Time-to-event curves were repre-
sented using Kaplan–Meier methods. Using logistic regression
methods, we generated a multivariable model for predictors of PPM.
Variables that were significantly different in the two PPM groups in
the univariable analysis (Tables 1-3) were included in the regression
model (p < .05). Computed tomography (CT) parameters were not
included in the model due to large numbers of missing data that would
weaken the model.
3 | RESULTS
Incidence of PPM in our population was 32.8% (82/250 patients).
Severe PPM was seen in 18 (7.2%) patients. Baseline demographic,
echocardiographic, CT, and procedural characteristics in patients with
and without PPM are shown in Table 1.
3.1 | Baseline characteristics
3.1.1 | Demographics, risk factors, and past
medical history
Female patients with PPM had a significantly higher BMI (27.4 ± 6.1
vs. 25.2 ± 5, p = .002). Hypertension, diabetes, smoking status, pre-
vious stroke, peripheral arterial disease, chronic kindey disease, pre-
vious cardiac surgery, or CABG did not differ between the two
groups (Table 1). Both groups had similar Euroscore I and STS
scores.
F IGURE 1 Incidence of patient prosthesis mismatch in various
groups. Balloon expandable transcatheter heart valves (THV) include
all the Edwards valves (S3, XT) and self-expanding THV all the
Medtronic iterations (CoreValve and Evolut R) [Color figure can be
viewed at wileyonlinelibrary.com]
TABLE 4 Multivariable regression
model identifying independent predictors
for patient-prosthesis mismatch
Model excluding interaction between valve type and valve size≤23 mm
OR 95% confidence interval p-value
BMI 1.077 1.02 1.14 .009
Valve type
Balloon expandable Ref
Self-expanding 0.669 0.32 1.39 .281
Others 1.552 0.70 3.42 .276
Valve ≤23 mm 3.385 1.77 6.46 <.001
Model including interaction between valve type and valve size ≤23 mm
OR 95% confidence interval p-value
BMI 1.075 1.02 1.14 .011
Valve type
Balloon expandable Ref
Self-expanding 0.498 0.18 1.40 .185
Others 1.994 0.62 6.40 .246
Valve ≤23 mm 3.003 1.14 7.94 .027
Valve type * valve ≤23 mm .203 (interaction test)
Abbreviations: BMI, body mass index; OR, odds ratio.
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3.1.2 | Echocardiographic data
Baseline echocardiographic data pre-TAVI were similar in the two
groups (Table 1). Baseline left ventricular ejection fraction was
54.6 ± 11.3 and 56.4 ± 10.5 in the PPM and no PPM groups, respec-
tively (p = .220). Peak and mean gradients alongside aortic valve area
were all similar in the two groups.
3.1.3 | CT parameters
CT measured aortic annulus perimeter (64.9 ± 21.5 PPM
vs. 71.6 ± 23.5 mm no PPM, p = .159) and aortic annular calcification
were similar in the two groups. There was a smaller minimal
iliofemoral dimension in patients with PPM (7.3 ± 2.3
vs. 8.5 ± 2.9 mm, p = .012) (Table 1).
No significant differences were seen in terms of coronary artery
disease severity.
3.2 | Female specific characteristics
With regards to female specific characteristics, there was a small
trend for increase in history of pregnancy amongst patients with
PPM post TAVI (Table 2). Gestational diabetes and hypertension,
age at menopause, history of HRT use, history of gynecological or
breast Ca and osteoporosis did not differ between the two
groups.
TABLE 5 One year follow-up
echocardiographic parameters
PPM = 1,
N = 82 (32.8%)
PPM = 0,
N = 168 (67.2%)
p-
value
LVEF 57.8 ± 9.1 58.5 ± 8.6 .650
Peak AV gradient (mmHg) 24.5 ± 13.0 19.8 ± 10.5 .040
Mean AV gradient (mmHg) 14.0 ± 5.9 10.7 ± 5.4 .001
Aortic paravalvular
regurgitation
.898
None 29 (55.8%) 37 (51.4%)
Mild 21 (40.4%) 32 (44.4%)
Moderate 2 (3.8%) 3 (4.2%)
Abbreviations: AV, aortic valve; LVEF, left ventricular ejection fraction; PPM, patient prosthesis
mismatch.
TABLE 6 Clinical outcomes in the
two groups at 30-days and 1-year
PPM = 1,
N = 82 (32.8%)
PPM = 0,
N = 168 (67.2%) p-value
30-day outcomes No. of events (%)
All-cause death 0 (0.0%) 3 (1.8%) .225
All stroke 0 (0.0%) 2 (1.2%) .322
Life-threatening bleeding 9 (11.0%) 19 (11.3%) .948
Acute kidney injury 2 (2.4%) 3 (1.8%) .728
Coronary artery obstruction 1 (1.2%) 2 (1.2%) .984
Major vascular complication 9 (11.0%) 14 (8.3%) .494
Valve-related dysfunction 0 (0.0%) 0 (0.0%) n.a
VARC2 early safety 21 (25.6%) 43 (25.6%) .888
1-year outcomes
Death 4 (4.9%) 14 (8.5%) .296
Cardiovascular death 2 (2.5%) 12 (7.4%) .122
Stroke 4 (4.9%) 5 (3.0%) .480
MACE (death, MI, stroke) 6 (7.3%) 19 (11.5%) .289
Death or stroke 6 (7.3%) 19 (11.5%) .289
Arrhythmia or conduction
disturbance
16 (19.5%) 36 (21.4%) .717
Abbreviations: MACE, major adverse cardiovascular endpoints; MI, myocardial infarction.
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3.3 | Procedural parameters
PPM was associated with significantly higher rates of balloon expand-
able valve implantation (48.8 vs. 33.1%) and significantly lower rates
of self-expanding valve implantation (26.3 vs. 52.8%, p < .001)
(Table 3). Patients in the PPM group were more frequently implanted
smaller sized valves (61 vs. 29.2% had valve size ≤23 mm, p < .001)
(Table 3, Figure 1 and Supplementary Table). There were no signifi-
cant differences in rates of new pacemaker, moderate paravalvular
leak, major vascular or bleeding complications.
3.4 | Predictors of PPM
In the multivariable regression model independent predictors of PPM
included raised BMI (per unit increase OR 1.08, (95%CI: 1.02–1.14)
and valve size equal to or under 23 mm (≤23 vs. >23, OR 3, 95%CI
1.14–7.94, p = .027). There was no significant interaction between
valve type and valve size p = .203. (Table 4).
3.5 | Follow-up
At 1-year echocardiographic follow-up there were significantly
increased peak and mean gradients across the aortic valve in the PPM
group (Table 5).
No significant differences were seen in VARC-2 early safety end-
point at 30-days (25.6% PPM group vs. 25.6% no PPM group,
p = .888) or in any of the clinical outcomes at 1 year (Table 6).
4 | DISCUSSION
In the current study, prevalence of PPM in this all-female TAVI cohort
was 32.8%. Independent predictors of PPM included larger BMI and
valve size ≤23 mm, whereas there was no interaction between valve
size and valve type. There does not appear to be any significant differ-
ence in 1-year clinical outcomes in the two groups; however, these
results should be interpreted cautiously given the small sample size of
our study and relatively short-term follow-up.
Despite several studies demonstrating that PPM incidence is
reduced when patients are treated with TAVI compared to SAVR,6,9 in
the current cohort nearly one third of females treated with TAVI
appear to have at least moderate PPM. This finding is important as
PPM has the potential implication of reduced LV hypertrophy regres-
sion and persistence of residual LV afterload11,27,28 which impacts on
coronary flow reserve.9 PPM post-TAVI has been associated with less
regression of LV hypertrophy, LV diastolic dysfunction, LV filling pres-
sure (measured by E/e'), less improvement in LV systolic function
(LVEF and myocardial strain), and less reduction of left atrial
volume.11,28,29
Interestingly, however, there may be a differential impact of PPM
on mortality in patients treated with TAVI and those with
SAVR.6,9,13,27,29 In the study by Pibarot et al9 an increased mortality
was seen in surgical patients with PPM but not in TAVI patients. In
that particular study, as in the current study, TAVI PPM patients had
significantly higher BMI, a previous shown independent predictor of
PPM.6 Body surface area greater than 1.88 m2 independently
predicted severe PPM with satisfactory sensitivity (0.71) and specific-
ity (0.70).30 A higher BMI has been shown to be a powerful indepen-
dent predictor of improved 2-year survival post TAVI in the
PARTNER-A TRIAL.31 Such a higher BMI was not seen in PPM
patients post surgery.9 Furthermore, indexing the EOA to the patient's
BSA may overestimate PPM severity in obese individuals.32 The
higher than expected valve gradient can be due, at least in part, to
patient's supranormal cardiac output and high flow state due to mor-
bid obesity.33 In the current study we did not identify any survival
benefit in females with no PPM, concurring with the study from
Pibarot et al9; however, the small patient numbers and reduced power
limit our ability to answer this question with certainty.
Smaller valve size (≤23 mm) was associated with PPM in our
cohort. Given that the CT annulus perimeter was not significantly
different in the two groups, and assuming optimal sizing, this can be
explained by valve choice (balloon expandable vs. self expanding).
This highlights the importance of optimal valve sizing based on CT
parameters34 and raises the question of a potential benefit in
implantation of supra-annular self-expanding valves in female
patients with small aortic annuli. In the randomized CHOICE
study,35 implantation of balloon-expandable valves was associated
with significantly reduced oversizing percent and significantly higher
mean transvalvular gradients (8.9 mmHg; 95% CI, 8.3–9.7
vs. 6.6 mmHg; 95%CI, 6.0–7.3; p < .001). In the same study, despite
having a significantly larger MSCT calculated aortic annulus perime-
ter, the balloon-expandable group ended up with a significantly
higher % of 23 mm valves (9.9 vs 1.7%, p < .001). Our results agreed
with the large retrospective TVT registry from Herrman et al on
62,125 TAVI patients which confirmed small valve size (≤23 mm) to
be a significant predictor of severe PPM.36
Previous studies have shown a hemodynamic benefit of TAVR
over SAVR in the subset of patients with small aortic annulus.9 In
high-risk patients with severe AS and a small aortic annulus (dia-
meter < 20 mm), TAVI compares favorably with currently available
surgical options, and may provide a reasonable alternative to conven-
tional AVR in elderly patients with a small aortic annulus.37 In a recent
meta-analysis,23 female AS patients treated with TAVI had improved
survival to those treated with SAVR and one of the potential explana-
tions was the presence of a larger iEOA post procedure. Therefore,
TAVI valve size and type selection becomes more important in
females who are known to have smaller size aortic annuli than their
male counterparts.38,39
In the current study no differences were observed in new pace-
maker rates, paravalvular leak, or major adverse cardiovascular events
in the PPM versus no PPM groups, probably secondary to improve-
ments in valve design and increasing operator experience. This is in
line with other studies which have shown no significant differences in
terms of major adverse cardiovascular, cerebrovascular and valve-
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related events, cardiac-related hospitalizations, improvement in func-
tional status, NYHA class, and self-assessed health state between
patients with PPM and those without PPM after TAVI.11,13,27,28,40,41
4.1 | Study limitations
One of the main limitations of the current study is the small sample
size. However, this represents the largest echocardiographic study on
PPM in female patients undergoing TAVI implantation. Another limita-
tion is the solely echocardiographic definition of PPM and absence of a
central echocardiographic core-lab. A recent study by Mooney et al,42
however, showed that even though the incidence of PPM was reduced
when EOA was estimated using left ventricular outflow tract measured
from CT (iEOACT), this did not associate with outcomes. Furthermore,
in that study it was the echo—iEOATTE and not the CT—iEOACT that
correlated with LV mass regression, posing questions on the clinical
value of the need for iEOACT. The small proportion of patients with
severe PPM (7.2%) may be the reason for the lack of differences in clin-
ical outcomes at 1-year. In the large TVT registry it was only the severe
PPM mismatch group that exhibited increased mortality at 1 year.36
However, even in patients with moderate PPM, differences in clinical
outcomes may only become evident at a later time (>5 years), due to
faster valve degeneration, as shown in surgical bioprosthetic valve
PPM registries.9 Detailed longitudinal data on LV mass, diastolic dys-
function, LV filling pressures, and LA size were lacking in the current
study. PPM may have a particular impact on these variables and should
be the focus of future longitudinal echocardiographic studies.
4.2 | Conclusions
PPM in female patients with AS undergoing TAVI is seen in almost
one third of cases. Main predictors include raised BMI and small valve
size. Appropriate sizing, and potentially use of self-expanding valves,
which allows for the use of larger valves in smaller anatomies, may
contribute to reduce the incidence of PPM. Even though in our study
at least moderate PPM was not associated with clinical endpoints,
results should be validated in larger, adequately powered cohorts.
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